Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02935790 | Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab | PHASE1 | COMPLETED | 1 | — | — | Sep 30, 2016 | Apr 7, 2017 | Aug 24, 2017 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| ACY-241 combo with Ipi and Nivo | EXPERIMENTAL | ACY-241 in Combination with Ipilimumab and Nivolumab |
| Name | Type | Description |
|---|---|---|
| ACY-241 | DRUG | tablet |
| nivolumab | DRUG | infusion |
| ipilimumab | DRUG | infusion |
Inclusion Criteria: 1. Patients must have signed and dated an Institutional Review Board/Independent Ethics Committee -approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures t...